Medical Imaging
April 1, 2026
A. Wismüller, A. Vosoughi, Akhil Kasturi
Functional magnetic resonance imaging (fMRI) in the resting state often involves analyzing thousands of potential connections with only a few hundred time points, presenting a significant challenge in causal modeling and topology inference of brain networks. This study evaluates whether large-scale Granger Causality (lsGC)—which uses principal component analysis and autoregressive modeling—can...
The British Journal of Psychiatry
April 1, 2026
Rashmi Patel
Summary Cannabis use increases the risk of psychosis, but cannabis-based medicinal products may provide additional therapeutic opportunities. Decriminalisation of cannabis has led to wider availability in certain jurisdictions, while in the UK regulated medicinal preparations are not readily accessible. A more balanced approach could reduce harms while maximising potential therapeutic benefits.
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
April 1, 2026
Daniel Bello, J. Connolly, Jean Addington et al.
BACKGROUND Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder,...
Drugs
April 1, 2026
Martha S. Rosenthal
This chapter examines cannabis, tracing its historical role in human history, concluding that it is one of humanity’s earliest cultivated plants. The chapter then looks at its use in medicine and rituals across ancient cultures. Globally, cannabis ranks as the most used illicit drug, with usage patterns influenced by factors such as age, gender, and geography. Legal and cultural perspectives...
Pharmacological Reports
April 1, 2026
Elmira Zolali, Mallory Burns, Sebastiano Intagliata et al.
BACKGROUND: Mu opioid receptor (MOR) agonists are the primary medication class used to treat moderate to severe pain; however, the ongoing opioid overdose crisis underscores the need for alternatives to MOR agonists for pain treatment. Delta9-tetrahydrocannabinol (THC), a cannabinoid CB1 receptor (CB1R) agonist, and sigma1 receptor (σ1R) antagonists elicit antinociceptive effects albeit less...
The journal of behavioral health services & research
April 1, 2026
Destin Rothe, Erica K Yuen, Kathleen A Moore et al.
Delta-8 THC is a psychoactive cannabinoid typically synthesized from hemp, with similar intoxicating effects as delta-9 THC. Surging public interest alongside the lack of federal regulation of delta-8 THC has led to an unclear legal landscape and increasing safety concerns. Educating young adults about the dangers of delta-8 THC is imperative. The current study investigated the effects of a...
Australasian Psychiatry
March 31, 2026
Shuichi Suetani, Faraz Honarparvar, Peter Muller et al.
Background Given that both attention-deficit hyperactivity disorder (ADHD) and cannabis use are known independent risk factors for psychosis, people with ADHD who consume cannabis may be especially vulnerable. The main objective of the current study was to explore the links between ADHD, cannabis use and psychosis outcomes. Methods A systematic review was conducted to examine the risk of...
Journal of Pakistan Psychiatric Society
March 30, 2026
Azizi Mohammad
Abstract Objective:To determine sociodemographic and clinical predictors of cannabis use among patients with first-episode psychosis (FEP) admitted to a tertiary care psychiatric unit in Pakistan. Methods:This cross-sectional study was conducted at the Psychiatry Unit, Khyber Teaching Hospital, Peshawar, from January 2021 to December 2024. Consecutive inpatients with FEP and no prior...
BMC Psychiatry
March 27, 2026
Samantha Carley, Robert B. Laprairie, Stephen Adams et al.
Abstract Background Psychotic disorders substantially impact individuals psychologically, occupationally, and socially. Although modifiable risk factors such as insecure attachment styles, history of psychological trauma, and substance use disorders (of which cannabis is the most frequent) are known to increase risk, it remains unclear how they may interact with each other to create pathways of...
International Journal of Innovative Technologies in Social Science
March 27, 2026
Artur Hawajski, Weronika Mielnicka, Johannes Nowak et al.
Background: Schizophrenia is a complex mental disorder influenced by both genetic and environmental factors. Cannabis use, particularly products with high tetrahydrocannabinol (THC) content, has been identified as a potential environmental risk factor for psychosis. Aim: This review aims to summarize current knowledge on the epidemiology, etiopathogenesis, and risk factors of schizophrenia,...